Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F Mosele, J Remon, J Mateo, CB Westphalen… - Annals of …, 2020 - Elsevier
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

AS Alzahrani - Seminars in cancer biology, 2019 - Elsevier
Abstract Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
signaling pathway is one of the major cellular signaling pathways that plays an important …

[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

J Pascual, G Attard, FC Bidard, G Curigliano… - Annals of …, 2022 - Elsevier
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

PI3K inhibitors are finally coming of age

B Vanhaesebroeck, MWD Perry, JR Brown… - Nature reviews Drug …, 2021 - nature.com
Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

L Yu, J Wei, P Liu - Seminars in cancer biology, 2022 - Elsevier
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

C Sweeney, S Bracarda, CN Sternberg, KN Chi… - The Lancet, 2021 - thelancet.com
Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …

Targeting Akt in cancer for precision therapy

H Hua, H Zhang, J Chen, J Wang, J Liu… - Journal of Hematology & …, 2021 - Springer
Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

Recent advances in targeted strategies for triple-negative breast cancer

S Zhu, Y Wu, B Song, M Yi, Y Yan, Q Mei… - Journal of Hematology & …, 2023 - Springer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Epidemiology and genomics of prostate cancer in Asian men

Y Zhu, M Mo, Y Wei, J Wu, J Pan, SJ Freedland… - Nature Reviews …, 2021 - nature.com
Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …

PI3K isoforms in cell signalling and vesicle trafficking

B Bilanges, Y Posor, B Vanhaesebroeck - Nature reviews Molecular …, 2019 - nature.com
PI3Ks are a family of lipid kinases that phosphorylate intracellular inositol lipids to regulate
signalling and intracellular vesicular traffic. Mammals have eight isoforms of PI3K, divided …